CC
IMVT icon

Commodore Capital’s Immunovant IMVT Stock Holding History

Commodore Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-750,990
Closed -$19.8M – 38
2024
Q2 		$19.8M Hold
750,990
– – 1.35% 22
2024
Q1 		$24.3M Sell
750,990
-249,010
-25% -$9.08M 1.62% 23
2023
Q4 		$42.1M Hold
1,000,000
– – 3.68% 8
2023
Q3 		$38.4M Buy
1,000,000
+100,000
+11% +$2.26M 4.49% 10
2023
Q2 		$17.1M Sell
900,000
-540,999
-38% -$10.1M 1.92% 17
2023
Q1 		$22.3M Buy
1,440,999
+290,494
+25% +$5.04M 3.4% 10
2022
Q4 		$20.4M Buy
+1,150,505
New +$14.5M 3.08% 11
2021
Q1 		– Sell
-83,782
Closed -$3.87M – 33
2020
Q4 		$3.87M Buy
+83,782
New +$3.87M 2.1% 23

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Commodore Capital's IMVT Position: Q3 2024 in Review

Commodore Capital sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 750,990 shares — an estimated $19.8M sold.

Commodore Capital first reported a position in IMVT in Q4 2020 and held it in 8 quarters. The position peaked at $42.1M in Q4 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Commodore Capital reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Commodore Capital sold 750,990 Immunovant shares in Q3 2024, an estimated $19.8M.
  • Commodore Capital first reported a position in Immunovant in Q4 2020 and held it in 8 quarters.
  • Commodore Capital's Immunovant position peaked at $42.1M in Q4 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Commodore Capital's 13F filing for Q3 2024, filed 14 Nov 2024.